| Bioactivity | DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of cancer through combination with radioactive elements. DOTA-Octreotide TFA can be used for the synthesis/research of Radionuclide-Drug Conjugates (RDCs)[1]. | ||||||
| Sequence | DOTA-{d-Phe}-Cys-Phe-{d-Trp}-Lys-Thr-Cys-{Threoninol} (Disulfide bridge: Cys2-Cys7) | ||||||
| Shortening | DOTA-{d-Phe}-CF-{d-Trp}-KTC-{Threoninol} (Disulfide bridge: Cys2-Cys7) | ||||||
| Formula | C67H93F3N14O19S2 | ||||||
| Molar Mass | 1519.66 | ||||||
| Appearance | 固体 | ||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||
| Storage | Sealed storage, away from moisture
*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
||||||
| Reference | [1]. Bodei L, et al., Receptor radionuclide therapy with 90Y-[DOTA]0-Tyr3-octreotide (90Y-DOTATOC) in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2004 Jul;31(7):1038-46. |
DOTA-Octreotide TFA
CAS: F: C67H93F3N14O19S2 W: 1519.66
DOTA-Octreotide TFA is composed of chelator DOTA and Octreotide (HY-P0036). DOTA-Octreotide TFA is used for research of
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.